Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7171640 | 0.79 | LMNA (0.32) | LMNA | |
| SCHEMBL17552002 | 0.75 | LMNA (0.36) | LMNA | |
| SCHEMBL10869225 | 0.75 | MEN1 (0.39) | — | |
| SCHEMBL16707607 | 0.74 | MEN1 (0.36) | — | |
| SCHEMBL9205718 | 0.72 | TLR8 (0.31) | — | |
| SCHEMBL10718494 | 0.70 | LMNA (0.39) | LMNA | |
| SCHEMBL6003760 | 0.70 | REV1 (0.30) | — | |
| SCHEMBL5925791 | 0.69 | — | — | |
| SCHEMBL23542846 | 0.68 | LMNA (0.42) | LMNA | |
| SCHEMBL1658541 | 0.68 | PDE10A (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090509-A1 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | Agouron Pharmaceuticals,Inc. | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090509-A1 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | CCNA1, PGF, CCNA2 | LMNA 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.